BPTC Promotes Jones and Ransohoff to Principal Consultants - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BPTC Promotes Jones and Ransohoff to Principal Consultants


Bioprocess Technology Consultants, Inc. (BPTC) a strategic, technical, and regulatory consulting company for the biopharmaceutical industry, has promoted Susan Dana Jones, PhD, and Thomas C. Ransohoff to principal consultants. As vice-presidents and principal consultants, they will continue to head client programs as well as assume greater management roles within the company.

Jones, who joined BPTC in 2002, is the co-founder of three l biotechnology companies and is known for her expertise in cell line development, cell culture, and process development for biopharmaceutical and vaccine products. She has managed multiple discovery and product development programs, and advises clients on manufacturing and regulatory issues. She is a member of the board of directors of Gene Solutions, LLC, the Symphogen A/S scientific advisory board, and the editorial advisory board of BioProcess International. Prior to joining BPTC, she was senior vice president of corporate development at Serenex, Inc. She received her bachelor of science degree in biochemistry from Harvard University, holds a doctorate in genetics from the University of California, San Francisco, and performed post-doctoral research at the Dana-Farber Cancer Institute of Harvard Medical School.

Ransohoff, who joined BPTC in 2002, has over 25 years of experience in the biopharmaceutical industry with expertise in the development and scale-up of biopharmaceutical processes; separations and purification technologies; process economic modeling; cGMP manufacturing; and management of technology-based start-up ventures. He guides clients through all stages of product development, advising on CMC strategy including regulatory, commercial, and manufacturing decisions. He is the cofounder of two biotechnology companies, and previously held senior level positions at TranXenoGen, Dyax, and Repligen. Ransohoff is a member of the editorial advisory board of BioPharm Magazine, and has served on a number of scientific and professional advisory boards. He has a bachelor of science degree from MIT and an Master’s degree from the University of California, Berkeley, both in Chemical Engineering.

Source: Bioprocess Technology Consultants

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here